Holen Sie sich die Stockscreener-App
28.22
5.56%
-1.66
Handel nachbörslich:
28.40
0.18
+0.64%
Schlusskurs vom Vortag:
$29.88
Offen:
$30.005
24-Stunden-Volumen:
1.70M
Relative Volume:
0.77
Marktkapitalisierung:
$3.46B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-7.199
EPS:
-3.92
Netto-Cashflow:
$-247.49M
1W Leistung:
-2.69%
1M Leistung:
-5.17%
6M Leistung:
+98.45%
1J Leistung:
+84.81%
1-Tages-Spanne:
$28.11
$30.75
1-Wochen-Bereich:
$28.11
$30.75
52-Wochen-Spanne:
$11.13
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Vergleichen Sie ARQT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
28.22 | 3.66B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Goldman | Neutral |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings - TechStock²
Earnings Report: Will Arcutis Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Rallies & Reliable Entry Point Trade Alerts - ulpravda.ru
Is Arcutis Biotherapeutics Inc. stock a buy before product launches2025 Key Highlights & Reliable Intraday Trade Plans - ulpravda.ru
How Arcutis Biotherapeutics Inc. stock compares to growth peersJuly 2025 News Drivers & Scalable Portfolio Growth Methods - ulpravda.ru
Arcutis Bio EVP Burnett sells $72k in shares By Investing.com - Investing.com Canada
Arcutis Bio EVP Burnett sells $72k in shares - Investing.com
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Revenue Surge and Analyst Consensus Signal Opportunity - DirectorsTalk Interviews
Arcutis BiotherapeuticsFocusing On ZORYVE Market Expansion And Pipeline Growth - RTTNews
(ARQT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Arcutis Biotherapeutics CEO Todd Watanabe sells $245,122 in shares - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $49,552.40 in Stock - MarketBeat
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares - Investing.com
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates - TechStock²
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day - ts2.tech
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4%Still a Buy? - MarketBeat
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Lowered by Zacks Research - MarketBeat
Arcutis Biotherapeutics Earnings Notes - Trefis
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3% - ts2.tech
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A 10.73% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Simplify Asset Management Inc. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Wall Street Zen to Buy - MarketBeat
Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
How Low Can Arcutis Biotherapeutics Stock Really Go? - Trefis
Why Arcutis Biotherapeutics Inc. stock remains resilientRate Cut & Weekly Watchlist of Top Performers - Улправда
Perpetual Ltd Increases Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics Inc. stock gain from strong economyJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance Australia
Is Arcutis Biotherapeutics Inc. stock attractive for growth ETFsJuly 2025 EndofMonth & Momentum Based Trading Ideas - DonanımHaber
Price Action: Why Arcutis Biotherapeutics Inc. stock remains resilientJuly 2025 Review & Low Risk Entry Point Tips - Улправда
Investor Mood: What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Selloffs & Weekly Setup with ROI Potential - Улправда
What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Spike Watch & Detailed Earnings Play Alerts - Улправда
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Squarepoint Ops LLC Has $2.35 Million Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 11,500 Shares of Stock - MarketBeat
Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest - Sahm
Arcutis Biotherapeutics Executive Sells Shares - TradingView — Track All Markets
Arcutis Biotherapeutics Insider Sold Shares Worth $332,851, According to a Recent SEC Filing - marketscreener.com
VP Burnett Sells 11,500 ($332.9K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView — Track All Markets
Arcutis (ARQT) CMO exercises options, sells 11,500 shares in plan trade - Stock Titan
This Biotech Stock Could Cure Your Portfolio's Pain - Finviz
Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals - Yahoo Finance
This biotech stock could cure your portfolio's pain - MSN
Arcutis Biotherapeutics, Inc. $ARQT Holdings Boosted by Frazier Life Sciences Management L.P. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):